Blue Horizon International does not offer or provide medical treatment or see patients within the United States. Our cellular and exosome products are investigational and are not approved by the U.S. FDA. This website is for informational and educational purposes only and is not medical advice.

Style Sampler

Layout Style

Patterns for Boxed Mode

Backgrounds for Boxed Mode

All fields are required.

Close Appointment form

IRB Approved Protocols

  • Home
  • IRB Approved Protocols

Nov. 30, 2021


“Retrospective Case Series Study of Dendritic Cell-Cytokine Induced Killer Cell Therapy in Previously Treated Subjects with Lymphatic Leukemia and Peritoneal Cancer”


Protocol #: BHI21-RCS-DCCIK
Institute of Regenerative and Cellular Medicine IRB Approval #: IRCM-2-21-308